NASDAQ
27.98USD
+0.47 (+1.71%)
We have scored 8 news catalysts on Galapagos N.V. (GLPG) over the past 12 months. The biggest single-day move next to one of them came Oct 21, 2025, when GLPG closed −8.6%: “PACCAR Posts Downbeat Earnings, Joins Neuphoria Therapeutics, Citius Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session”. Coverage across the window leans mixed (average ticker sentiment −0.04). Most of the impact sits in sector healthcare and short squeeze potential.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
1.8B
P/E
—
EPS
—
Beta
0.30
52W range
24.74-37.78
Day range
27.50–28.09
Open
27.50
Prev close
27.51
Volume
2.4K
Avg volume
153.2K
Dividend
0.00
IPO
2012-02-27
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Galapagos N.V. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for GLPG: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.
